Sarepta Therapeutics Inc (SRPT)
61.98
-1.84
(-2.89%)
USD |
NASDAQ |
Apr 01, 16:00
62.34
+0.36
(+0.59%)
After-Hours: 16:14
Sarepta Therapeutics Enterprise Value: 5.975B for March 31, 2025
View 4,000+ Financial Data Types:
Add
Browse
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna Inc | 3.936B |
| Biomarin Pharmaceutical Inc | 12.94B |
| Gilead Sciences Inc | 154.60B |
| Vertex Pharmaceuticals Inc | 118.38B |
| Madrigal Pharmaceuticals Inc | 6.505B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 159.05M |
| Revenue (Quarterly) | 658.41M |
| Total Expenses (Quarterly) | 496.73M |
| EPS Diluted (Quarterly) | 1.50 |
| Gross Profit Margin (Quarterly) | 79.91% |
| Profit Margin (Quarterly) | 24.16% |
| Earnings Yield | 3.68% |
| Operating Earnings Yield | 3.15% |
| Normalized Earnings Yield | 3.788 |